Cas:439081-18-2 Afatinib manufacturer & supplier

Chemical Name:Afatinib

CAS.NO:439081-18-2

Synonyms:2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)-, (2E)-;(S,E)-N-(4-((3-chloro-4-fluorophenyl)amino)-7-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)-4-(dimethylamino)but-2-enamide;(2E)-N-(4-[(3-chloro-4-fluorophenyl)amino]-7-{[(3S)-tetrahydrofuran-3-yl]oxy}quinazolin-6-yl)-4-(dimethylamino)but-2-enamide;Afatinib;Tovok;Tomtovok;BIBW2992;(2E)-N-{4-[(3-Chloro-4-fluorophenyl)amino]-7-[(3S)-tetrahydro-3-furanyloxy]-6-quinazolinyl}-4-(dimethylamino)-2-butenamide;Gilotrif;BIBW 2992

Molecular Formula:C₂₄H₂₅ClFN₅O₃

Molecular Weight:485.938

HS Code:2934999090

Physical and Chemical Properties:

Melting point:100 – 102 °C

Boiling point:676.9±55.0 °C at 760 mmHg

Density:1.4±0.1 g/cm3

Index of Refraction:1.668

PSA:88.61000

Exact Mass:485.162994

LogP:3.59

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)-, (2E)- chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,BIBW 2992 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Tomtovok Use and application,Gilotrif technical grade,usp/ep/jp grade.

Related News: One key question for the fixed-duration combo is whether it can sustain remission after treatment has stopped. In the preliminary analysis of the GLOW trial, at three months after treatment ended, 51.9% of the Imbruvica-Venclexta patients had undetectable measurable residual disease (uMRD)—a stringent marker reflecting no signs of cancer—in bone marrow, versus 17.1% for the control group. The rates for peripheral blood were 54.7% and 39% for the two groups, respectively. Afatinib manufacturer However, the study did not produce any significant benefits when it came to thinking, reasoning and memory tests performed across the entire patient group — possibly because there were too few people with clinically diagnosed Alzheimer’s participating in the trial. Afatinib supplier However, the study did not produce any significant benefits when it came to thinking, reasoning and memory tests performed across the entire patient group — possibly because there were too few people with clinically diagnosed Alzheimer’s participating in the trial. Afatinib vendor It is delivered to hospitals and pharmacies until it reaches the patient. Afatinib factory Over the years, large international pharmaceutical companies have gradually focused on the research and development and sales of patented drugs, and have gradually outsourced traditional products. Among them, most of the contractors are pharmaceutical companies in emerging countries.